We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Paratek Pharmaceuticals Inc | NASDAQ:PRTK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.23 | 2.18 | 2.23 | 0 | 01:00:00 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13E-3
(Amendment No. 3)
RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e)
OF THE SECURITIES EXCHANGE ACT OF 1934
Paratek Pharmaceuticals, Inc.
(Name of the Issuer)
Paratek Pharmaceuticals, Inc.
GPC WH Fund LP
Novo Holdings A/S
Resistance GP LLC
Resistance TopCo L.P.
Resistance Holdings, Inc.
Resistance Intermediate, Inc.
Resistance Acquisition, Inc.
Resistance Merger Sub, Inc.
Evan Loh, M.D.
(Names of Persons Filing Statement)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
699374302
(CUSIP Number of Class of Securities)
William M. Haskel Chief Legal Officer, General Counsel and Corporate Secretary Paratek Pharmaceuticals, Inc. 75 Park Plaza Boston, MA 02116 (617) 807-6600 |
Adam Dilluvio Resistance Acquisition, Inc. c/o Gurnet Point Capital, LLC 55 Cambridge Parkway, Suite 401 Cambridge, MA 02142 (617) 588-4900 |
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Persons Filing Statement)
With copies to
Tara Fisher Christopher Comeau Ropes & Gray LLP Prudential Tower 800 Boylston Street Boston, MA 02199 (617) 951-7000 |
Peter N. Handrinos Leah R. Sauter Elisabeth M. Martin Latham & Watkins LLP 200 Clarendon Street Boston, MA 02116 (617) 948-6000 |
This statement is filed in connection with (check the appropriate box):
a. | ☒ | The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under the Securities Exchange Act of 1934. | ||
b. | ☐ | The filing of a registration statement under the Securities Act of 1933. | ||
c. | ☐ | A tender offer. | ||
d. | ☐ | None of the above. |
Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: ☐
Check the following box if the filing is a final amendment reporting the results of the transaction: ☐
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of this transaction, passed upon the merits or fairness of this transaction, or passed upon the adequacy or accuracy of the disclosure in this Transaction Statement on Schedule 13E-3. Any representation to the contrary is a criminal offense.
INTRODUCTION
This Amendment No. 3 (this Amendment No. 3), which amends and supplements the Rule 13E-3 Transaction Statement on Schedule 13E-3 filed on June 30, 2023 with the Securities and Exchange Commission (the SEC) (as amended by Amendment No. 2 filed with the SEC on August 3, 2023 and Amendment No. 1 filed with the SEC on July 28, 2023, the Schedule 13E-3 or Transaction Statement), is being filed with the SEC pursuant to Section 13(e) of the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the Exchange Act), jointly by the following persons (each, a Filing Person, and collectively, the Filing Persons): (i) Paratek Pharmaceuticals, Inc. (the Company), a Delaware corporation and the issuer of the common stock, par value $0.001 per share (the Company Common Stock), that is subject to the Rule 13e-3 transaction, (ii) GPC WH Fund LP, a Delaware limited partnership (the Guarantor); (iii) Resistance GP LLC, a Delaware limited liability company (Resistance GP); (iv) Novo Holdings A/S, a Danish limited liability company (Novo Holdings); (v) Resistance TopCo L.P. a Delaware limited partnership (TopCo); (vi) Resistance Holdings, Inc., a Delaware corporation (Resistance Holdings); (vii) Resistance Intermediate, Inc., a Delaware corporation (Resistance Intermediate); (viii) Resistance Acquisition, Inc., a Delaware corporation (Parent); (ix) Resistance Merger Sub, Inc., a Delaware corporation (Merger Sub and, together with the Guarantor, Resistance GP, Novo Holdings, TopCo, Resistance Holdings, Resistance Intermediate and Parent, the Parent Entities); and (x) Evan Loh. The Parent Entities are Filing Persons of this Transaction Statement because they may be deemed to be affiliates of the Company under a possible interpretation of the SEC rules governing going-private transactions.
On June 6, 2023, Parent, Merger Sub and the Company entered into an Agreement and Plan of Merger (as amended, restated, supplemented or otherwise modified from time to time, the Merger Agreement), which provides for, among other things, the merger of Merger Sub with and into the Company (the Merger), with the Company surviving the Merger as a direct wholly-owned subsidiary of Parent. On August 2, 2023, the Company filed with the SEC a definitive proxy statement (the Proxy Statement) under Regulation 14A of the Exchange Act, relating to a special meeting of the stockholders of the Company (the Special Meeting) at which the stockholders of the Company will consider and vote upon a proposal to approve and adopt the Merger Agreement and cast a non-binding, advisory vote to approve certain items of compensation that are based on or otherwise related to the Merger and may become payable to certain named executive officers of the Company under existing agreements with the Company. Concurrently with the filing of this Amendment No. 3, the Company is filing definitive additional materials under Regulation 14A of the Exchange Act (the Supplement, a copy of which is attached hereto as Exhibit (a)(2)(iii)) to amend and supplement the Proxy Statement. The adoption of the Merger Agreement will require the affirmative vote of the holders of a majority of the outstanding Company Common Stock entitled to vote on such matters at a stockholders meeting duly called and held for such purpose. A copy of the Proxy Statement is attached hereto as Exhibit (a)(2)(i). A copy of the Merger Agreement is attached as Annex A to the Proxy Statement and incorporated herein by reference.
Under the terms of the Merger Agreement, if the Merger is completed, each Share, other than as provided below, will be converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the Cash Consideration) but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one contractual contingent value right (a CVR) that shall represent the right to receive $0.85 upon the satisfaction of certain conditions, pursuant to a Contingent Value Rights Agreement (the CVR Agreement) to be entered into between Parent and a rights agent selected by Parent and reasonably acceptable to the Company (the Rights Agent) (the Cash Consideration and one CVR, collectively, the Merger Consideration). The following company Common Stock will not be converted into the right to receive the per Share Merger Consideration in connection with the Merger: (i) each Share held in the treasury of the Company or owned by the Company or any direct or indirect wholly-owned subsidiary of the Company and each Share owned by Parent, Merger Sub or any direct or indirect wholly-owned subsidiary of Parent or Merger Sub immediately prior to the effective time of the Merger (the Effective Time) or (ii) Company Common Stock outstanding immediately prior to the Effective Time and held by stockholders who are entitled to demand, and properly demand, appraisal for such Company Common Stock in accordance with Section 262 of the Delaware General Corporation Law.
On June 6, 2023, concurrently with the execution and delivery of the Merger Agreement, certain management employees and former management employees of the Company (the Subscribers) entered into a subscription agreement (the Subscription Agreement) with TopCo and the Company, pursuant to which, immediately after the Effective Time, each Subscriber subscribes for a number of non-voting common units of TopCo based on the Subscribers gross, pre-tax payments under the Companys Revenue Performance Incentive Plan that become due in connection with the closing. For certain Subscribers, the Subscription Agreement further provides that the equity award consideration that becomes payable after the closing pursuant to the terms of the Merger Agreement may be settled in the form of cash or vested non-voting common units of TopCo with a fair market value, as of the payment date, equal to the amount of equity award consideration that has become payable; provided, that the Company will retain a number of TopCo units sufficient to satisfy all withholding taxes that become due with respect to the equity award consideration.
1
The Merger remains subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, including the approval and adoption of the Merger Agreement by the Companys stockholders.
The cross-references below are being supplied pursuant to General Instruction G to Schedule 13E-3 and show the location in the Proxy Statement of the information required to be included in response to the items of Schedule 13E-3. Pursuant to General Instruction F to Schedule 13E-3, the information contained in the Proxy Statement, including all appendices thereto, is incorporated in its entirety herein by reference, and the responses to each item in this Schedule 13E-3 are qualified in their entirety by the information contained in the Proxy Statement and the appendices thereto.
Capitalized terms used but not expressly defined in this Schedule 13E-3 shall have the respective meanings given to them in the Proxy Statement.
The information concerning the Company contained in, or incorporated by reference into this Schedule 13E-3 and the Proxy Statement was supplied by the Company. Similarly, all information concerning each other Filing Person contained in, or incorporated by reference into this Schedule 13E-3 and the Proxy Statement was supplied by such Filing Person. No Filing Person, including the Company, is responsible for the accuracy of any information supplied by any other Filing Person.
While each of the Filing Persons acknowledges that the Merger is a going private transaction for purposes of Rule 13E-3 under the Exchange Act, the filing of this Transaction Statement shall not be construed as an admission by any Filing Person, or by any affiliate of a Filing Person, that the Company is controlled by any Filing Person.
2
Item 1. | Summary Term Sheet |
The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
Item 2. | Subject Company Information |
(a) Name and Address. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
PARTIES TO THE MERGERThe Company
(b) Securities. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
INFORMATION ABOUT THE SPECIAL MEETING Record Date and Quorum
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Market Price of Shares and Dividends
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Beneficial Ownership of Common Stock by Management and Directors
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Beneficial Ownership of Common Stock by Principal Stockholders
(c) Trading Market and Price. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Market Price of Shares and Dividends
(d) Dividends. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Market Price of Shares and Dividends
(e) Prior Public Offerings. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Prior Public Offerings
(f) Prior Stock Purchases. The information set forth in the Proxy Statement under the following caption is incorporated herein by reference:
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Certain Transactions in the Shares
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Past Contracts, Transactions, Negotiations and Agreements
3
Item 3. | Identity and Background of Filing Person |
(a) (c) Name and Address; Business and Background of Entities; Business and Background of Natural Persons. Paratek Pharmaceuticals, Inc. is the subject company. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
PARTIES TO THE MERGER
OTHER INTERESTED PARTIES IN THE MERGER
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY
Item 4. | Terms of the Transaction |
(a)(1) Tender Offers. Not Applicable.
(a)(2) Mergers or Similar Transactions. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Position of Parent Entities as to the Fairness of the Merger
SPECIAL FACTORS Purpose and Reasons of the Parent Entities for the Merger
SPECIAL FACTORS Position of Dr. Loh as to the Fairness of the Merger
SPECIAL FACTORS Purpose and Reasons of Dr. Loh for the Merger
SPECIAL FACTORS Plans for the Company After the Merger
SPECIAL FACTORS Certain Effects of the Merger
SPECIAL FACTORS Interests of Executive Officers and Directors of the Company in the Merger
SPECIAL FACTORS Material U.S. Federal Income Tax Consequences of the Merger
SPECIAL FACTORS Financing of the Merger
THE MERGER AGREEMENT
SPECIAL FACTORS Accounting Treatment
INFORMATION ABOUT THE SPECIAL MEETING Vote Required
4
Annex A The Merger Agreement
Annex B Form of CVR Agreement
(c) Different Terms. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
SPECIAL FACTORS Plans for the Company After the Merger
SPECIAL FACTORS Certain Effects of the Merger
SPECIAL FACTORS Interests of Executive Officers and Directors of the Company in the Merger
SPECIAL FACTORS Voting Agreement
SPECIAL FACTORS Subscription Agreement
THE MERGER AGREEMENT Treatment of Equity Awards and Company Warrants
THE MERGER AGREEMENT Employment and Employee Benefits Matters
MERGER RELATED EXECUTIVE COMPENSATION ARRANGEMENTS (THE MANAGEMENT COMPENSATION PROPOSAL PROPOSAL 2)
Annex A The Merger Agreement
Annex B Form of CVR Agreement
Annex C Voting Agreement
(d) Appraisal Rights. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SPECIAL FACTORS Appraisal Rights
THE MERGER AGREEMENT Dissenters Rights
INFORMATION ABOUT THE SPECIAL MEETING Appraisal Rights
THE MERGER (THE MERGER AGREEMENT PROPOSAL PROPOSAL 1) Appraisal Rights
Annex A The Merger Agreement
Annex E Section 262 of the General Corporation Law of the State of Delaware
(e) Provisions for Unaffiliated Security Holders. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Provisions for the Companys Stockholders
5
(f) Eligibility for Listing or Trading. Not Applicable.
Item 5. | Past Contracts, Transactions, Negotiations and Agreements |
(a) Transactions. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Interests of Executive Officers and Directors of the Company in the Merger
THE MERGER AGREEMENT
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Certain Transactions in the Shares
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Past Contracts, Transactions, Negotiations and Agreements
WHERE YOU CAN FIND MORE INFORMATION
Annex A The Merger Agreement
Annex B Form of CVR Agreement
(b) Significant Corporate Events. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Plans for the Company After the Merger
SPECIAL FACTORS Certain Effects of the Merger
SPECIAL FACTORS Interests of Executive Officers and Directors of the Company in the Merger
SPECIAL FACTORS Financing of the Merger
SPECIAL FACTORS Limited Guarantee
SPECIAL FACTORS Voting Agreement
SPECIAL FACTORS Subscription Agreement
THE MERGER AGREEMENT
MERGER RELATED EXECUTIVE COMPENSATION ARRANGEMENTS (THE MANAGEMENT COMPENSATION PROPOSAL PROPOSAL 2)
6
Annex A The Merger Agreement
Annex B Form of CVR Agreement
Annex C Voting Agreement
(c) Negotiations or Contacts. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Interests of Executive Officers and Directors of the Company in the Merger
MERGER RELATED EXECUTIVE COMPENSATION ARRANGEMENTS (THE MANAGEMENT COMPENSATION PROPOSAL PROPOSAL 2)
(e) Agreements Involving the Subject Companys Securities. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Plans for the Company After the Merger
SPECIAL FACTORS Certain Effects of the Merger
SPECIAL FACTORS Interests of Executive Officers and Directors of the Company in the Merger
SPECIAL FACTORS Intent of the Directors and Executive Officers to Vote in Favor of the Merger
SPECIAL FACTORS Commitment of Dr. Loh to Vote in Favor of the Merger
SPECIAL FACTORS Financing of the Merger
SPECIAL FACTORS Limited Guarantee
SPECIAL FACTORS Voting Agreement
SPECIAL FACTORS Subscription Agreement
THE MERGER AGREEMENT
MERGER RELATED EXECUTIVE COMPENSATION ARRANGEMENTS (THE MANAGEMENT COMPENSATION PROPOSAL PROPOSAL 2)
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Certain Transactions in the Shares
WHERE YOU CAN FIND MORE INFORMATION
Annex A The Merger Agreement
Annex B Form of CVR Agreement
Annex C Voting Agreement
7
Item 6. | Purposes of the Transaction and Plans or Proposals |
(b) Use of Securities Acquired. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SPECIAL FACTORS Plans for the Company After the Merger
SPECIAL FACTORS Certain Effects of the Merger
SPECIAL FACTORS Payment of Merger Consideration
THE MERGER AGREEMENT
DELISTING AND DEREGISTRATION OF COMMON STOCK
Annex A The Merger Agreement
Annex B Form of CVR Agreement
(c)(1) (8) Plans. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Position of Parent Entities as to the Fairness of the Merger
SPECIAL FACTORS Purpose and Reasons of the Parent Entities for the Merger
SPECIAL FACTORS Position of Dr. Loh as to the Fairness of the Merger
SPECIAL FACTORS Purpose and Reasons of Dr. Loh for the Merger
SPECIAL FACTORS Plans for the Company After the Merger
SPECIAL FACTORS Certain Effects of the Merger
SPECIAL FACTORS Interests of Executive Officers and Directors of the Company in the Merger
SPECIAL FACTORS Intent of the Directors and Executive Officers to Vote in Favor of the Merger
SPECIAL FACTORS Commitment of Dr. Loh to Vote in Favor of the Merger
SPECIAL FACTORS Financing of the Merger
SPECIAL FACTORS Limited Guarantee
SPECIAL FACTORS Voting Agreement
SPECIAL FACTORS Subscription Agreement
8
THE MERGER AGREEMENT
INFORMATION ABOUT THE SPECIAL MEETING
MERGER RELATED EXECUTIVE COMPENSATION ARRANGEMENTS (THE MANAGEMENT COMPENSATION PROPOSAL PROPOSAL 2)
DELISTING AND DEREGISTRATION OF COMMON STOCK
Annex A The Merger Agreement
Annex B Form of CVR Agreement
Annex C Voting Agreement
Item 7. Purposes, Alternatives, Reasons and Effects
(a) Purposes. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Position of Parent Entities as to the Fairness of the Merger
SPECIAL FACTORS Purpose and Reasons of the Parent Entities for the Merger
SPECIAL FACTORS Position of Dr. Loh as to the Fairness of the Merger
SPECIAL FACTORS Purpose and Reasons of Dr. Loh for the Merger
SPECIAL FACTORS Plans for the Company After the Merger
SPECIAL FACTORS Certain Effects of the Merger
(b) Alternatives. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Position of Parent Entities as to the Fairness of the Merger
SPECIAL FACTORS Purpose and Reasons of the Parent Entities for the Merger
SPECIAL FACTORS Position of Dr. Loh as to the Fairness of the Merger
9
SPECIAL FACTORS Purpose and Reasons of Dr. Loh for the Merger
SPECIAL FACTORS Certain Effects on the Company if the Merger is Not Completed
(c) Reasons. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Opinion of the Companys Financial Advisor
SPECIAL FACTORS Position of Parent Entities as to the Fairness of the Merger
SPECIAL FACTORS Purpose and Reasons of the Parent Entities for the Merger
SPECIAL FACTORS Position of Dr. Loh as to the Fairness of the Merger
SPECIAL FACTORS Purpose and Reasons of Dr. Loh for the Merger
SPECIAL FACTORS Plans for the Company After the Merger
SPECIAL FACTORS Certain Effects of the Merger
Annex D Opinion of the Companys Financial Advisor
(d) Effects. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Position of Parent Entities as to the Fairness of the Merger
SPECIAL FACTORS Purpose and Reasons of the Parent Entities for the Merger
SPECIAL FACTORS Position of Dr. Loh as to the Fairness of the Merger
SPECIAL FACTORS Purpose and Reasons of Dr. Loh for the Merger
SPECIAL FACTORS Plans for the Company After the Merger
SPECIAL FACTORS Certain Effects of the Merger
SPECIAL FACTORS Certain Effects on the Company if the Merger is Not Completed
SPECIAL FACTORS Interests of Executive Officers and Directors of the Company in the Merger
10
SPECIAL FACTORS Material U.S. Federal Income Tax Consequences of the Merger
SPECIAL FACTORS Fees and Expenses
SPECIAL FACTORS Accounting Treatment
SPECIAL FACTORS Payment of Merger Consideration
THE MERGER AGREEMENT The Merger
THE MERGER AGREEMENT The Merger Consideration
THE MERGER AGREEMENT Impact of Stock Splits, Etc.
THE MERGER AGREEMENT Treatment of Equity Awards and Company Warrants
THE MERGER AGREEMENT Exchange Procedures and Payment Procedures
THE MERGER AGREEMENT Withholding
THE MERGER AGREEMENT Dissenters Rights
THE MERGER AGREEMENT Organizational Documents, Directors and Officers of the Surviving Corporation
THE MERGER AGREEMENT Delisting and Deregistration
THE MERGER AGREEMENT Employment and Employee Benefits Matters
THE MERGER AGREEMENT Indemnification; Directors and Officers Insurance
MERGER RELATED EXECUTIVE COMPENSATION ARRANGEMENTS (THE MANAGEMENT COMPENSATION PROPOSAL PROPOSAL 2)
DELISTING AND DEREGISTRATION OF COMMON STOCK
Annex A The Merger Agreement
Annex B Form of CVR Agreement
Item 8. Fairness of the Transaction
(a), (b) Fairness; Factors Considered in Determining Fairness. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Opinion of the Companys Financial Advisor
11
SPECIAL FACTORS Position of Parent Entities as to the Fairness of the Merger
SPECIAL FACTORS Position of Dr. Loh as to the Fairness of the Merger
SPECIAL FACTORS Interests of Executive Officers and Directors of the Company in the Merger
THE MERGER AGREEMENT Indemnification; Directors and Officers Insurance
Annex D Opinion of the Companys Financial Advisor
(c) Approval of Security Holders. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
THE MERGER AGREEMENT Company Stockholder Approval
THE MERGER AGREEMENT Conditions to the Completion of the Merger
INFORMATION ABOUT THE SPECIAL MEETING Record Date and Quorum
INFORMATION ABOUT THE SPECIAL MEETING Vote Required
INFORMATION ABOUT THE SPECIAL MEETING Voting
INFORMATION ABOUT THE SPECIAL MEETING How to Vote
INFORMATION ABOUT THE SPECIAL MEETING Proxies and Revocation
THE MERGER (THE MERGER AGREEMENT PROPOSAL PROPOSAL 1)
Annex A The Merger Agreement
Annex B Form of CVR Agreement
(d) Unaffiliated Representative. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Opinion of the Companys Financial Advisor
SPECIAL FACTORS Provisions for the Companys Stockholders
(e) Approval of Directors. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
12
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Intent of the Directors and Executive Officers to Vote in Favor of the Merger
INFORMATION ABOUT THE SPECIAL MEETING Recommendation of the Company Board
INFORMATION ABOUT THE SPECIAL MEETING Voting Intentions of the Companys Directors and Executive Officers
THE MERGER (THE MERGER AGREEMENT PROPOSAL PROPOSAL 1) Vote Recommendation
(f) Other Offers. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
THE MERGER AGREEMENT Acquisition Proposals
Annex A The Merger Agreement
Item 9. | Reports, Opinions, Appraisals and Negotiations |
(a) (c) Report, Opinion or Appraisal; Preparer and Summary of the Report, Opinion or Appraisal; Availability of Documents. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference.
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Opinion of the Companys Financial Advisor
SPECIAL FACTORS Position of Parent Entities as to the Fairness of the Merger
SPECIAL FACTORS Position of Dr. Loh as to the Fairness of the Merger
WHERE YOU CAN FIND MORE INFORMATION
Annex D Opinion of the Companys Financial Advisor
13
The Presentation Materials dated December 21, 2022, prepared by Moelis & Company LLC and reviewed by the Company Board (as defined in the Proxy Statement), are attached hereto as Exhibit (c)(ii)
The Presentation Materials dated May 26, 2023, prepared by Moelis & Company LLC and reviewed by the Company Board (as defined in the Proxy Statement), are attached hereto as Exhibit (c)(iii)
The Presentation Materials dated June 6, 2023, prepared by Moelis & Company LLC and reviewed by the Company Board (as defined in the Proxy Statement), are attached hereto as Exhibit (c)(iv)
Item 10. Source and Amount of Funds or Other Consideration
(a), (b) Source of Funds; Conditions. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
SPECIAL FACTORS Financing of the Merger
SPECIAL FACTORS Limited Guarantee
THE MERGER AGREEMENT Closing and Effective Time of the Merger
THE MERGER AGREEMENT Closing of the Merger
THE MERGER AGREEMENT Covenants Related to the Companys Conduct of Business
THE MERGER AGREEMENT Parent Financing and Company Cooperation
THE MERGER AGREEMENT Conditions to the Completion of the Merger
Annex A The Merger Agreement
(c) Expenses. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SPECIAL FACTORS Fees and Expenses
THE MERGER AGREEMENT Termination
THE MERGER AGREEMENT Termination Fees
THE MERGER AGREEMENT Expenses
INFORMATION ABOUT THE SPECIAL MEETING Solicitation of Proxies; Payment of Solicitation Expenses
Annex A The Merger Agreement
(d) Borrowed Funds.
SPECIAL FACTORS Financing of the Merger
THE MERGER AGREEMENT Parent Financing and Company Cooperation
14
Item 11. | Interest in Securities of the Subject Company |
(a) Securities Ownership. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
SPECIAL FACTORS Interests of Executive Officers and Directors of the Company in the Merger
SPECIAL FACTORS Voting Agreement
INFORMATION ABOUT THE SPECIAL MEETING Record Date and Quorum
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Beneficial Ownership of Common Stock by Management and Directors
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Beneficial Ownership of Common Stock by Principal Stockholders
Annex C Voting Agreement
(b) Securities Transactions. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Interests of Executive Officers and Directors of the Company in the Merger
SPECIAL FACTORS Voting Agreement
SPECIAL FACTORS Subscription Agreement
THE MERGER AGREEMENT
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Certain Transactions in the Shares
Annex A The Merger Agreement
Annex B Form of CVR Agreement
Annex C Voting Agreement
Item 12. The Solicitation or Recommendation
(d) Intent to Tender or Vote in a Going-Private Transaction. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Interests of Executive Officers and Directors of the Company in the Merger
15
SPECIAL FACTORS Intent of the Directors and Executive Officers to Vote in Favor of the Merger
SPECIAL FACTORS Commitment of Dr. Loh to Vote in Favor of the Merger
SPECIAL FACTORS Voting Agreement
INFORMATION ABOUT THE SPECIAL MEETING Recommendation of the Company Board
INFORMATION ABOUT THE SPECIAL MEETING Voting Intentions of the Companys Directors and Executive Officers
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Beneficial Ownership of Common Stock by Management and Directors
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Beneficial Ownership of Common Stock by Principal Stockholders
Annex C Voting Agreement
(e) Recommendation of Others. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Position of Parent Entities as to the Fairness of the Merger
SPECIAL FACTORS Purpose and Reasons of the Parent Entities for the Merger
SPECIAL FACTORS Position of Dr. Loh as to the Fairness of the Merger
SPECIAL FACTORS Purpose and Reasons of Dr. Loh for the Merger
INFORMATION ABOUT THE SPECIAL MEETING Recommendation of the Company Board
Item 13. | Financial Statements |
(a) Financial Information. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Selected Historical Consolidated Financial Data
OTHER IMPORTANT INFORMATION REGARDING THE COMPANY Book Value per Share
WHERE YOU CAN FIND MORE INFORMATION
16
(b) Pro Forma Information. Not Applicable.
Item 14. Persons/Assets, Retained, Employed, Compensated or Used
(a) Solicitations or Recommendations. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
SPECIAL FACTORS Fees and Expenses
INFORMATION ABOUT THE SPECIAL MEETING Solicitation of Proxies; Payment of Solicitation Expenses
(b) Employees and Corporate Assets. The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
QUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND THE SPECIAL MEETING
SPECIAL FACTORS Background of the Merger
SPECIAL FACTORS Considerations of the Company Board and Procedural Safeguards with respect to the Contemplated Transactions
INFORMATION ABOUT THE SPECIAL MEETING
INFORMATION ABOUT THE SPECIAL MEETING Solicitation of Proxies; Payment of Solicitation Expenses
Item 15. | Additional Information |
(b) The information set forth in the Proxy Statement under the following captions is incorporated herein by reference:
SUMMARY TERM SHEET
SPECIAL FACTORS Interests of Executive Officers and Directors of the Company in the Merger
SPECIAL FACTORS Certain Effects of the Merger
THE MERGER AGREEMENT
MERGER RELATED EXECUTIVE COMPENSATION ARRANGEMENTS (THE MANAGEMENT COMPENSATION PROPOSAL PROPOSAL 2)
Annex A The Merger Agreement
17
(c) Other Material Information. The entirety of the Proxy Statement, including all appendices thereto, is incorporated herein by reference.
18
Item 16. | Exhibits |
The following exhibits are filed herewith:
# | Confidential treatment has been requested for certain information contained in this exhibit. Such information has been omitted and filed separately with the Securities and Exchange Commission. |
* | Previously filed. |
19
* | Previously filed. |
20
SIGNATURES
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
PARATEK PHARMACEUTICALS, INC. | ||
By: | /s/ William M. Haskel | |
Name: | William M. Haskel | |
Title: | Chief Legal Officer, General Counsel and Corporate Secretary |
Date: September 11, 2023
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
GPC WH FUND LP by B-FLEXION International GP LLC, its General Partner | ||
By: | /s/ Ronald Cami | |
Name: | Ronald Cami | |
Title: | Authorized Signatory | |
By: | /s/ Adam Dilluvio | |
Name: | Adam Dilluvio | |
Title: | General Counsel |
Date: September 11, 2023
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
NOVO HOLDINGS A/S | ||
By: | /s/ Barbara Fiorini Due | |
Name: | Barbara Fiorini Due | |
Title: | General Counsel |
Date: September 11, 2023
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
RESISTANCE GP LLC | ||
By: | /s/ Adam Dilluvio | |
Name: | Adam Dilluvio | |
Title: | Secretary and Treasurer of the General Partner of the Sole Member |
Date: September 11, 2023
21
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
RESISTANCE TOPCO L.P. | ||
By: | /s/ Adam Dilluvio | |
Name: | Adam Dilluvio | |
Title: | Secretary and Treasurer of the General Partner of the Sole Member of the General Partner |
Date: September 11, 2023
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
RESISTANCE HOLDINGS, INC. | ||
By: | /s/ Adam Dilluvio | |
Name: | Adam Dilluvio | |
Title: | Secretary and Treasurer |
Date: September 11, 2023
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
RESISTANCE INTERMEDIATE, INC. | ||
By: | /s/ Adam Dilluvio | |
Name: | Adam Dilluvio | |
Title: | Secretary and Treasurer |
Date: September 11, 2023
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
RESISTANCE ACQUISITION, INC. | ||
By: | /s/ Adam Dilluvio | |
Name: | Adam Dilluvio | |
Title: | Secretary and Treasurer |
Date: September 11, 2023
22
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
RESISTANCE MERGER SUB, INC. | ||
By: | /s/ Adam Dilluvio | |
Name: | Adam Dilluvio | |
Title: | Secretary and Treasurer |
Date: September 11, 2023
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
/s/ Evan Loh, M.D. |
Evan Loh, M.D. |
Date: September 11, 2023
23
1 Year Paratek Pharmaceuticals Chart |
1 Month Paratek Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions